| |MARCH 20258PHILIPS, MEDTRONIC PARTNER TO TRAIN 300+ CLINICIANS IN HEART IMAGINGGLENMARK'S US GROWTH CONTINUES WITH ACETYLCYSTEINE INJECTION LAUNCHIn India, a Memorandum of Understanding (MoU) was signed by Philips, a leader in health technology, and Medtronic, a leader in medical technology, to teach and train radiologists and cardiologists in new imaging methods for structural heart disorders. Through this collaboration, more than 300 clinicians will gain advanced skills in multimodal imaging, including magnetic resonance imaging (MRI) and echocardiogram (echo), particularly for patients with end-stage renal disease (ESRD).Under the direction of well-known international and Indian specialists, the training program will mix didactic sessions with practical experience given on Philips' state-of-the-art ultrasound and MRI devices. For these training workshops, 15 important medical facilities with expertise in structural heart surgeries have been selected."As India's healthcare landscape progresses to address its high disease burden, we remain committed to enhancing clinical expertise and making a meaningful impact on patient care," Bharath Sesha, managing director, Philips Indian Subcontinent, said.Global studies show that 9.5 percent of ESRD patients with aortic stenosis can benefit from advanced imaging technologies during transcatheter aortic valve replacement (TAVR), and the rising incidence of chronic kidney disease (CKD) in India adds about 2.2 lakh new cases of ESRD annually. As a result, there is an urgent need for advanced diagnostic tools and specialized training for clinicians. POGlenmark Pharmaceuticals Ltd has also established itself in the US market by acquiring Aspen Pharma USA Inc's generic injectable Acetylcysteine. The acquisition, whose value remains confidential, aligns with Glenmark's strategy to enhance its hospital segment functions.The resultant drug--Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) in single-use vials--is employed for the treatment of acetaminophen overdose. The company's introduction assures that its medication is anticipated to demonstrate the same therapeutic benefits as Acetadote Injection from Cumberland Pharmaceuticals Inc.Commenting on the development, Marc Kikuchi, Glenmark President & Business Head in North America, said, "This is a great addition to our injectable portfolio in the US market as we continue to drive growth for the hospital segment."Glenmark Pharmaceuticals has been advancing in the international generic market, concentrating on complex generics and injectables. Leveraging its robust research-led model, the company has brought to market a chain of products that are specially positioned to cater to the needs of critical care. This buy is in line with Glenmark's strategy of building its injectable portfolio and further making its mark in the competitive US pharma market. POTOP STORIES
< Page 7 | Page 9 >